Analysts have been eager to weigh in on the Healthcare sector with new ratings on Hims & Hers Health (HIMS – Research Report) and Novo ...

Super Micro has until Tuesday to file delayed financial accounts or risk being delisted by the Nasdaq stock exchange, ...

Citi raised the firm’s price target on Hims & Hers to $27 from $25 and keeps a Sell rating on the shares post the Q4 report. The focus on ...

Krystena Murray is suing a fertility clinic after discovering the child she gave birth to was not her biological child due to ...

The Olsen twins, now 38, who were once rarely off TV screens after their debut on Full House, are now based in New York City ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Hims & Hers delivered Q4 2024 earnings that saw the stock sell off nearly 20% after hours. Find out why I rate HIMS stock a ...

Hims & Hers dipped 19% post-Q4 earnings. Read here for HIMS stock's growth trends, margin concerns, and why this could be a ...

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...

Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its ...

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...